Department of Cardiology, General Hospital of Shenyang Military Region, PLA, Shenyang 110840, China.
Front Med. 2011 Dec;5(4):395-400. doi: 10.1007/s11684-011-0167-1. Epub 2011 Dec 27.
Although first-generation drug-eluting stents (DES) have markedly reduced restenosis, complications of late and very late in-stent thrombosis have emerged as prime limitations to this technology. The development of new DES is a key process to prevent these complications. Translational research plays a very important role in experiments which determine the safety and efficacy of DES before human clinical trials. The present review focuses on translational research of novel DES, including drug discovery, creation of preclinical research models, planning and conducting of first-in-man studies, and developing next-generation DES systems.
虽然第一代药物洗脱支架（DES）显著降低了再狭窄，但晚期和极晚期支架内血栓形成的并发症已成为该技术的主要限制因素。开发新型 DES 是预防这些并发症的关键过程。转化研究在确定 DES 在人体临床试验前的安全性和疗效的实验中起着非常重要的作用。本文重点介绍新型 DES 的转化研究，包括药物发现、临床前研究模型的建立、首例人体研究的规划和开展以及下一代 DES 系统的开发。
